Cellectis SA (NASDAQ:CLLS) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET
Company Participants
Arthur Stril - Chief Business Officer
Andre Choulika - Co-founder, CEO& Director
Mark Frattini - Chief Medical Officer
Bing Wang - CFO
Conference Call Participants
Dev Prasad - Jefferies
Hartaj Singh - Oppenheimer
Jack Allen - Robert W. Baird & Co.
Silvan Tuerkcan - JMP Securities
Whitney Watson - Goldman Sachs
Operator
Good morning, everyone, and welcome to the Cellectis Third Quarter 2023 Earnings Calls. [Operator Instructions].
I'd now like to introduce the first speaker Arthur Stril, Chief Business Officer. You may begin.
Arthur Stril
Good morning, and welcome, everyone, to Cellectis third quarter 2023 corporate update and financial results conference call. Joining me on the call today with prepared remarks are Dr.Andre Choulika , our Chief Executive Officer; Dr. Bing Wang, our Chief Financial Officer; and Dr.Mark Frattini our Chief Medical Officer.
Yesterday evening, Cellectis issued a press release reporting a corporate and business update for the third quarter 2023 and its financial results for the nine- month period ended September 30, 2023.
As a reminder, we will make statements regarding Celectis financial outlook, including the sufficiency of cash from operations in addition to its manufacturing, regulatory and product development status and plan and product development of its license partners.
These forward statements, which are based on management's current expectations, and assumption and on information currently available to management, including information provided or otherwise publicly reported by our license partners are subject to risks and uncertainties that may cause actual results to differ from those forecasted.
A description of these risks can be found in our most recent Form 20F filed with the Securities and Exchange Commission SEC and the financial report including the management report for the ended on December 31, 2022, and subsequent filing Cellectis makes with the SEC from time to time.
I would now like to turn the call over to Andre.
Andre Choulika
Thank you, Arthur, and good morning, and thank you, everyone, for joining us today. Last week, we announced a strategic collaboration and investment agreement with AstraZeneca.
We are very proud to initiate this partnership with one of the top leaders in the pharma space, pairing our strong commitment and ambition cell and gene therapy, AstraZeneca, because we have been very much impressed by the long term strategy in this space. Backed by a strong commitment and development already made paving the way powered by top leadership in this arena.